Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

1.33USD
7 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.33
Open
$1.35
Day's High
$1.35
Day's Low
$1.33
Volume
35,102
Avg. Vol
45,828
52-wk High
$4.95
52-wk Low
$1.09

Latest Key Developments (Source: Significant Developments)

Heat Biologics reports quarterly loss per share at $0.16
Thursday, 15 Nov 2018 08:20am EST 

Nov 15 (Reuters) - Heat Biologics Inc ::QUARTERLY LOSS PER SHARE $0.16.AS OF SEPTEMBER 30, 2018, COMPANY HAD APPROXIMATELY $21.0 MILLION IN CASH AND CASH EQUIVALENTS - SEC FILING.  Full Article

Heat Biologics Quarterly Loss Per Share $0.27
Tuesday, 14 Aug 2018 08:17am EDT 

Aug 14 (Reuters) - Heat Biologics Inc ::QUARTERLY LOSS PER SHARE $0.27.ON TRACK TO REPORT KEY CLINICAL MILESTONES BEGINNING IN Q4 2018.Q2 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.QTRLY REVENUE $1.1 MILLION VERSUS $411,000.  Full Article

Heat Biologics Inc - QTRLY Loss Per Share $0.75
Tuesday, 15 May 2018 07:27am EDT 

May 15 (Reuters) - Heat Biologics Inc ::HEAT BIOLOGICS INC - QTRLY LOSS PER SHARE $0.75.  Full Article

Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock
Friday, 30 Mar 2018 06:34am EDT 

March 30 (Reuters) - Heat Biologics Inc ::FILES FOR OFFERING OF UP TO $15 MILLION OF ITS COMMON STOCK - SEC FILING.  Full Article

Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1
Wednesday, 28 Feb 2018 07:04am EST 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB.HEAT BIOLOGICS SAYS COMBINATION OF HS-110 AND NIVOLUMAB WAS WELL TOLERATED - SEC FILING.HEAT BIOLOGICS - IN PHASE 2 CLINICAL TRIAL OF HS-110 AND NIVOLUMAB, OVERALL RESPONSES APPEARED DURABLE AND LONG LASTING‍​.  Full Article

Heat Biologics Gets Recommendation To Continue Patient Enrollment Of Ongoing Phase 2 Clinical Trial
Tuesday, 20 Feb 2018 01:59pm EST 

Feb 20 (Reuters) - Heat Biologics Inc ::SAYS GOT INDEPENDENT DMC RECOMMENDATION TO CONTINUE PATIENT ENROLLMENT OF ONGOING PHASE 2 CLINICAL TRIAL FOR HS-110 AND NIVOLUMAB​.  Full Article

Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial
Thursday, 7 Dec 2017 07:15am EST 

Dec 7 (Reuters) - Heat Biologics Inc ::SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL.HEAT BIOLOGICS - RECEIVED WRITTEN RESPONSES FROM U.S. FDA REGARDING HS-110 TRIAL DESIGN FOR TREATMENT OF NON-SMALL CELL LUNG CANCER.HEAT BIOLOGICS - FDA AGREED THAT TRIAL DESIGNS, BOTH SINGLE-ARM AND CONTROLLED, WOULD BE APPROPRIATE TO SUPPORT REGISTRATIONAL TRIAL OF HS-110.HEAT BIOLOGICS - TRIAL DESIGN DETAILS AND NEXT STEPS EXPECTED TO BE ANNOUNCED FOLLOWING READ-OUT OF PHASE 2 DATA, ANTICIPATED IN 2H 2018.  Full Article

Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​
Monday, 13 Nov 2017 07:12am EST 

Nov 13 (Reuters) - Heat Biologics Inc :Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​.Heat Biologics Inc - ‍cash and cash equivalents totaled approximately $4.3 million, as of September 30, 2017​.  Full Article

Heat Biologics Inc files for mixed shelf of up to $50 million ‍​
Monday, 30 Oct 2017 10:21am EDT 

Oct 30 (Reuters) - Heat Biologics Inc :Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​.  Full Article

SELEXIS SA AND PELICAN THERAPEUTICS SIGN AGREEMENT TO ADVANCE PELICAN’S IMMUNOTHERAPY CLINICAL PROGRAMS
Wednesday, 4 Oct 2017 08:00am EDT 

Oct 4 (Reuters) - Selexis SA::SELEXIS SA AND PELICAN THERAPEUTICS SIGN AGREEMENT TO ADVANCE PELICAN’S IMMUNOTHERAPY CLINICAL PROGRAMS.SELEXIS SA - CO, PELICAN THERAPEUTICS ENTERED INTO SERVICE AGREEMENT TO ADVANCE DEVELOPMENT OF PELICAN'S PROPRIETARY IMMUNOTHERAPY CLINICAL CANDIDATES.  Full Article

Heat-stable drug could save thousands from post-childbirth bleeding: WHO

LONDON A new formulation of a drug to prevent excessive bleeding in women after they give birth could save thousands of lives in poorer countries, according to a study co-led by the World Health Organization (WHO).